ProCE Banner Activity

Phase III CONVERT: Twice-Daily vs Once-Daily Concurrent CRT in Limited-Stage SCLC

Slideset Download
Conference Coverage
Concurrent CRT using modern RT techniques produced similar rates of survival and toxicity whether given once daily or twice daily for limited-stage SCLC.

Released: June 07, 2016

Expiration: June 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals